Inventiva Reports Investigator-Initiated P-II Trial Results of Lanifibranor for Type 2 Diabetes and Nonalcoholic Fatty Liver Disease
Shots:
- The P-II trial evaluating lanifibranor (800mg/day for 24wks.) vs PBO in 38 patients. The study was conducted by Dr. Kenneth Cusi from the University of Florida
- The study met the primary efficacy EPs i.e., 44% vs 12% reduction of IHTG. The result was consistent with the P-IIb trial (NATIVE) which showed a significant effect on steatosis reduction, ≥30% liver triglyceride reduction (65% vs 22%); NAFLD resolution (25% vs 0%) defined as IHTG ≤5.5%
- Significant effect on a series of 2EPs incl. glycemic control, atherogenic dyslipidemia, hepatic insulin action, insulin-stimulated muscle glucose disposal & amelioration of the adipose tissue dysfunction with an increase in plasma adiponectin while an additional 2EPs incl. a series of markers of cardiometabolic health
Ref: Inventiva | Image: Inventiva
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
